GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Acadia Pharmaceuticals Inc. (ACAD) [hlAlert]

Rating:
Mkt Outperform
ACAD
up 697.24 %

Acadia Pharmaceuticals Inc. (ACAD) upgraded to Mkt Outperform with price target $7 by JMP Securities

Posted on: Tuesday,  May 5, 2009  8:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on 05/05/2009, when the stock price was $2.54.
Since then, Acadia Pharmaceuticals Inc. has gained 697.24% as of 07/18/2014's recent price of $20.25.
If you would have followed this JMP Securities's recommendation on ACAD, you would have gained 697.24% of your investment in 1900 days.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson?s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company?s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/5/2009 8:25 AM Buy
None
2.54 7.00
as of 12/31/2009
1 Week up  23.70 %
1 Month up  35.77 %
3 Months down  -2.33 %
1 YTD down  -34.25 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/6/2008 10:25 AM Hold
None
2.68
12/12/2007 8:25 AM Buy
None
12.22

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy